Can tumor diversity predict chemotherapy success in Triple-Negative breast cancer?

NCT ID NCT03077776

Ongoing Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why some tumors disappear completely with chemotherapy while others do not, which could help tailor treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Biopsy procedure
What this could lead to: If successful, this could help doctors predict which patients with triple-negative breast cancer will respond to chemotherapy, potentially guiding more personalized treatment plans.
What could go wrong: This is an observational study, so it won't directly test a new treatment. The findings may not lead to immediate changes in care, and biopsies carry small risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE-NEGATIVE BREAST NEOPLASM

Contacts and locations

Locations

Centre Eugène Marquis

Rennes, France
Centre George François Leclerc

Dijon, France
Centre Jean Perrin

Clermont-Ferrand, France
Centre Leon Bérard

Lyon, France
Centre Paul Strauss

Strasbourg, France
Gustave Roussy

Villejuif, France
Hopitaux universitaire de strasbourg - Hopital civil

Strasbourg, France
Institut Paoli Calmettes

Marseille, France
Institut de Cancerologie de l'Ouest

Nantes, France
Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France